Qiagen (NYSE:QGEN) Stock Rating Upgraded by Deutsche Bank Aktiengesellschaft

Key Points

• Deutsche Bank Aktiengesellschaft upgraded Qiagen from a "hold" to a "buy" and set a $54 price target, implying roughly a 30.91% upside from the prior close.
• Analyst sentiment is mixed—five Buys, seven Holds and one Sell—leaving a MarketBeat consensus rating of "Hold" with an average price target of $55.20.
• Qiagen slightly beat quarterly estimates with $0.62 EPS and $540.4M revenue, but the stock trades around $41.25 (near its 1‑year low); market cap is about $8.71B and P/E is ~20.5.

Qiagen (NYSE:QGEN - Get Free Report) was upgraded by equities research analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "buy" rating in a research report issued on Friday, MarketBeat Ratings reports. The brokerage currently has a $54.00 price target on the stock. Deutsche Bank Aktiengesellschaft's target price would suggest a potential upside of 30.91% from the stock's previous close.

Several other equities analysts have also commented on QGEN. Barclays set a $58.00 price target on Qiagen and gave the company an "overweight" rating in a research note on Friday, February 6th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $59.00 target price on shares of Qiagen in a research report on Thursday, February 5th. Stifel Nicolaus set a $50.00 target price on shares of Qiagen and gave the stock a "hold" rating in a research note on Friday, February 6th. Citigroup dropped their price target on shares of Qiagen from $55.40 to $55.00 and set a "neutral" rating for the company in a research report on Friday, February 6th. Finally, Zacks Research lowered shares of Qiagen from a "hold" rating to a "strong sell" rating in a report on Monday. Five investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $55.20.

Qiagen Trading Up 0.3%

NYSE:QGEN traded up $0.13 on Friday, hitting $41.25. The stock had a trading volume of 614,472 shares, compared to its average volume of 2,617,715. The company has a fifty day moving average price of $49.45 and a two-hundred day moving average price of $48.94. Qiagen has a 1-year low of $40.14 and a 1-year high of $57.81. The company has a quick ratio of 3.31, a current ratio of 3.90 and a debt-to-equity ratio of 0.44. The stock has a market cap of $8.71 billion, a price-to-earnings ratio of 20.48, a PEG ratio of 2.01 and a beta of 0.70.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Thursday, February 5th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.61 by $0.01. The firm had revenue of $540.42 million for the quarter, compared to analyst estimates of $528.53 million. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.61 EPS. Equities research analysts expect that Qiagen will post 2.26 earnings per share for the current fiscal year.

Institutional Trading of Qiagen

Several hedge funds have recently made changes to their positions in the business. Johnson Investment Counsel Inc. grew its holdings in shares of Qiagen by 0.4% in the third quarter. Johnson Investment Counsel Inc. now owns 57,359 shares of the company's stock valued at $2,563,000 after purchasing an additional 240 shares in the last quarter. Allworth Financial LP boosted its position in Qiagen by 23.2% in the 3rd quarter. Allworth Financial LP now owns 1,358 shares of the company's stock valued at $61,000 after buying an additional 256 shares during the period. Bessemer Group Inc. grew its stake in shares of Qiagen by 0.5% in the third quarter. Bessemer Group Inc. now owns 51,780 shares of the company's stock worth $2,288,000 after acquiring an additional 262 shares in the last quarter. Banque Cantonale Vaudoise increased its position in shares of Qiagen by 1.8% during the fourth quarter. Banque Cantonale Vaudoise now owns 16,363 shares of the company's stock worth $747,000 after acquiring an additional 290 shares during the period. Finally, Commerce Bank raised its stake in shares of Qiagen by 4.9% in the fourth quarter. Commerce Bank now owns 6,725 shares of the company's stock valued at $302,000 after acquiring an additional 314 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company's stock.

Qiagen Company Profile

Qiagen NV NYSE: QGEN is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.